Hansoh Pharmaceutical Group (HKG:3692) subsidiaries Shanghai Hansoh Biomedical and Jiangsu Hansoh Pharmaceutical Group signed a global license deal for their diabetes and weight loss drug candidate, HS-10535, according to Hong Kong bourse filing Wednesday.
A Merck Sharp & Dohme subsidiary will pay up to $2 billion to acquire the global license to develop, manufacture, and commercialize HS-10535, which includes a $112 million upfront payment and up to $1.9 billion in milestone payments, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。